Fighting Influenza from Behind the Counter: A Treatment Review
Treatment GuidelinesBaloxavir MarboxilConsiderations for Treatment DecisionsREFERENCES1. Preliminary Estimated Flu Disease Burden 2024-2025 Flu Season. CDC. January 3, 2025. Accessed January 9, 2025. https://www.cdc.gov/flu-burden/php/data-vis/2024-2025.html2. Uyeki Tm, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019;68(6):e1-e47. doi:10.1093/cid.ciy8663. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014:348:g2545. doi:10.1136/bmj.g25454. Oseltamivir phosphate [prescribing information]. Genentech; updated August 2019. Accessed January 9, 2025. https://www.gene.com/download/pdf/tamiflu_prescribing.pdf5. Nakamura Y, Sugawara T, Ohkusa Y, et al. Life-threatening abnormal behavior incidence in 10-19 year old patients administered neuraminidase inhibitors. PLoS One. 2015;10(7):e0129712. doi:10.1371/journal.pone.01297126. Harrington R, Adimadhyam S, Lee TA, Schumock GT, Antoon JW. The relationship between oseltamivir and suicide in pediatric patients. Ann Fam Med. 2018;16(2):145-148. doi:10.1370/afm.21837. Huh K, Kang M, Shin DH, Hong J, Jung J. Oseltamivir and the risk of neuropsychiatric events: a national, population-based study. Clin Infect Dis. 2020;71(9):e409-e414. doi:10.1093/cid/ciaa0558. Baloxavir marboxil [prescribing information]. Genentech; updated March 2024. Accessed January 9, 2025. https://www.gene.com/download/pdf/xofluza_prescribing.pdf9. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379(10):913-923. doi:10.1056/NEJMoa171619710. Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomized, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020;20(10):1204-1214. doi:10.1016/S1473-3099(20)30004-911. Baker J, Block SL, Matharu B, et al. Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2). Pediatr Infect Dis J. 2020;39(8):700-705. doi:10.1097/INF.000000000000274712. Baker JB, Block SL, Cagas SE, et al. Safety and efficacy of baloxavir marboxil in influenza-infected children 5-11 years of age: a post hoc analysis of a phase 3 study. Pediatr Infect Dis J. 2023;42(11):983-989. doi:10.1097/INF.000000000000406213. Baloxavir marboxil for prophylaxis against influenza in household contacts. N Engl J Med. 2020;383(4):309-320. doi:10.1056/NEJMoa1915341
Leave a Reply